Leaders in Cannabis Formulations: Part 4 – LifeTonic

In this series of articles, Aaron Green sits down and interviews a number of industry scientists and executives leading cannabis formulation companies. In Part 3, Green chats with Russell Thomas, CEO of Vapor Distilled and LifeTonic Brands, to learn more about their evaporative extraction technology and ionized cannabinoid products.

The post Leaders in Cannabis Formulations: Part 4 – LifeTonic appeared first on Cannabis Industry Journal.

Amazon Now Backs Federal Legalization

In a blog post published yesterday, Amazon’s Senior Vice President, Dave Clark, announced the company’s support for the MORE Act and their updated drug testing policy.

The post Amazon Now Backs Federal Legalization appeared first on Cannabis Industry Journal.

Leaders in Cannabis Formulations: Part 2

In this series of articles, Aaron Green sits down and interviews a number of industry scientists and executives leading cannabis formulation companies. In Part 2, Green chats with Jesse Lopez, CEO and Founder of Geocann, a global cannabis organization based in Fort Collins, Colorado with technical formulation expertise and the exclusive global rights to multi-patented drug delivery system technologies.

The post Leaders in Cannabis Formulations: Part 2 appeared first on Cannabis Industry Journal.

FDA Issues Warning Letters on Marketing and Sale of OTC CBD Products

The FDA issued warning letters to two companies this month, alleging FD&C Act violations stemming from marketing new drugs without approval. Companies marketing CBD products should be careful not to market OTC drugs containing CBD.

The post FDA Issues Warning Letters on Marketing and Sale of OTC CBD Products appeared first on Cannabis Industry Journal.

GMPs & Cannabis Manufacturing

Kathleen May, Founder of Triskele Quality Solutions, provides a roadmap to Good Manufacturing Practices (GMPs) compliance for manufacturers in the cannabis industry.

The post GMPs & Cannabis Manufacturing appeared first on Cannabis Industry Journal.

Jazz Pharmaceuticals to Acquire GW Pharma

In a press release published last week, the two companies announced they have entered an agreement for Jazz to acquire GW Pharma, the producer of the only FDA-approved CBD medication Epidiolex, for a total of $7.2 billion.

The post Jazz Pharmaceuticals to Acquire GW Pharma appeared first on Cannabis Industry Journal.